.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,925,331

« Back to Dashboard

Details for Patent: 5,925,331

Title: Technetium-99m labeled peptides for thrombus imaging
Abstract:This invention relates to radiolabeled reagents that are scintigraphic imaging agents for imaging sites of thrombus formation in vivo, and methods for producing such reagents. Specifically, the invention relates to reagents each comprised of a specific binding compound, capable of binding to at least one component of a thrombus, covalently linked to a radiolabel-binding moiety. The invention provides these reagents, methods and kits for making such reagents, and methods for using such reagents labeled with technetium-99m to image thrombus sites in a mammalian body.
Inventor(s): Dean; Richard T. (Bedford, NH), Lister-James; John (Bedford, NH)
Assignee: Diatide, Inc. (Londonderry, NH)
Filing Date:Jan 05, 1995
Application Number:08/335,832
Claims:1. A reagent for preparing a scintigraphic imaging agent for imaging a thrombus within a mammalian body comprising a specific binding compound capable of binding to at least one component of a thrombus, covalently linked to a technetium-99m binding moiety, wherein the technetium-99m binding moiety has the formula:

wherein C(pgp).sup.s is a cysteine having a protect thiol group and (aa) is an amino acid.

2. The reagent of claim 1 that is radiolabeled with technetium-99m.

3. The reagent of claim 1 wherein the specific binding compound and C(pgp).sup.s -(aa)-C(pgp).sup.s are covalently linked through from about one to about 20 amino acids.

4. The reagent of claim 1 wherein each of the protected cysteines comprising the technetium-99m binding moiety has a protecting group of the formula

wherein R is a lower alkyl having 1 to 6 carbon atoms, 2-,3-,4-pyridyl, phenyl, or phenyl substituted with lower alkyl, hydroxy, lower alkoxy, carboxy, or lower alkoxycarbonyl.

5. The reagent of claim 1 wherein C(pgp).sup.s -(aa)-C(pgp).sup.s has the formula: ##STR14## .

6. The reagent of claim 1 wherein the specific binding compound is a peptide comprising 4 to 100 amino acids.

7. The reagent of claim 6 selected from the group consisting of: ##STR15## C.sub.Acm GC.sub.Acm GGRGDS, C.sub.Acm GC.sub.Acm GGRGDGGRGDS,

C.sub.Acm GC.sub.Acm GGRGDGGRGDGGRGDS,

C.sub.Acm GC.sub.Acm RRRRRRRRRGDV,

GRGDVKC.sub.Acm GC.sub.Acm.amide,

GRGDVC.sub.Acm GC.sub.Acm.amide,

GRGDVRGDFKC.sub.Acm GC.sub.Acm.amide,

GRGDVRGDFC.sub.Acm GC.sub.Acm.amide,

acetyl-G.Apc.GDV.Apc.GDFKC.sub.Acm GC.sub.Acm.amide,

G.Apc.GCV.Apc.GDFKC.sub.Acm GC.sub.Acm.amide,

G.Aklpc.GDVKC.sub.Acm GC.sub.Acm.amide,

(CC.sub.Acm GC.sub.Acm GGRGDS).sub.3 --TSEA,

C.sub.Acm GC.sub.Acm NDGDFEEIPEEYLQ,

C.sub.Acm GC.sub.Acm GGF.sub.D PRPGGGGNGDFEEIPEEYL,

C.sub.Acm GC.sub.Acm GGF.sub.D PRPGamide,

{(GPRP).sub.2 K}.sub.2 KC.sub.Acm GC.sub.Acm.amide,

(GPRVVERHQSA).sub.2 KC.sub.Acm GC.sub.Acm.amide,

(GPRPC.sub.Acm GC.sub.Acm C).sub.3 --TSEA,

[GPRPPPGGC.sub.Acm GC.sub.Acm GGC].sub.3 --TSEA, ##STR16## acetyl-RRARGDDLDC.sub.Acm GC.sub.Acm.amide, and PSPSPIHPAHHKRDRRQC.sub.Acm GC.sub.Acm.amide.

8. A complex formed by reacting the reagent of claim 1 with technetium-99m in the presence of a reducing agent.

9. The complex of claim 8, wherein the reducing agent is selected from the group consisting of a dithionite ion, a stannous ion and a ferrous ion.

10. A complex formed by labeling the reagent of claim 1 with technetium-99m by ligand exchange of a prereduced technetium-99m complex.

11. A kit for preparing a radiopharmaceutical preparation, said kit comprising a sealed vial containing a predetermined quantity of the reagent of claim 1 and a sufficient amount of reducing agent to label the reagent with technetium-99m.

12. A method for labeling a reagent according to claim 1 comprising reacting the reagent with technetium-99m in the presence of a reducing agent.

13. The method of claim 12, wherein the reducing agent is selected from the group consisting of a dithionite ion, a stannous ion and a ferrous ion.

14. A method for imaging a thrombus within a mammalian body comprising the steps of administering an effective diagnostic amount of the technetium-99m radiolabeled reagent of claim 2 to an animal and detecting the radiolabeled reagent localized at the site of a thrombus.

15. The reagent according to claim 1 wherein the specific-binding peptide is chemically synthesized in vitro.

16. The reagent according to claim 15 wherein the specific-binding peptide is synthesized by solid phase peptide synthesis.

17. The reagent according to claim 15 wherein the radiolabel-binding moiety is covalently linked to the specific-binding peptide during in vitro chemical synthesis.

18. The reagent according to claim 17 wherein the radiolabel-binding moiety is covalently linked to the specific-binding peptide during solid phase peptide synthesis.

19. A composition of matter comprising a reagent selected from the group consisting of: ##STR17## C.sub.Acm GC.sub.Acm GGRGDS, C.sub.Acm GC.sub.Acm GGRGDGGRGDS,

C.sub.Acm GC.sub.Acm GGRGDGGRGDGGRGDS,

C.sub.Acm GC.sub.Acm RRRRRRRRRGDV,

GRGDVKC.sub.Acm GC.sub.Acm.amide,

GRGDVC.sub.Acm GC.sub.Acm.amide,

GRGDVRGDFKC.sub.Acm GC.sub.Acm.amide,

GRGDVRGDFC.sub.Acm GC.sub.Acm.amide,

acetyl-G.apc.GDV.Apc.GDFKC.sub.Acm GC.sub.Acm.amide,

G.Apc.GDV.Apc.GDFKC.sub.Acm GC.sub.Acm.amide,

G.Apc.GDVKC.sub.Acm GC.sub.Acm.amide,

(CC.sub.Acm GC.sub.Acm GGRGDS).sub.3 --TSEA,

C.sub.Acm GC.sub.Acm NDGDFEEIPEEYLQ,

C.sub.Acm GC.sub.Acm GGF.sub.D PRPGGGGNGDFEEIPEEYL,

C.sub.Acm GC.sub.Acm GGF.sub.D PRPGamide,

{(GPRP).sub.2 K}.sub.2 KC.sub.Acm GC.sub.Acm.amide,

(GPRVVERHQSA).sub.2 KC.sub.Acm GC.sub.Acm.amide,

(GPRPC.sub.Acm GC.sub.Acm C).sub.3 --TSEA, ##STR18## .

20. The reagent of claim 1 wherein the reagent further comprises a polyvalent linking moiety covalently linked to a multiplicity of specific binding compounds and also covalently linked to a multiplicity of radiolabel-binding moieties to comprise a reagent for preparing a multimeric polyvalent scintigraphic imaging agent; wherein the molecular weight of the multimeric polyvalent scintigraphic imaging agent is less than about 20,000 daltons.

21. The reagent of claim 20 wherein the polyvalent linking moiety is bis-succinimidylmethylether, 4-(2,2-dimethylacetyl)benzoic acid, N-[2-(N',N'-bis(2-succinimidoethyl)aminoethyl)]--N.sup.6,N.sup.9 -bis(2-methyl-2-mercaptopropyl)-6,9-diazanonanamide, tris(succinimidylethyl)amine, bis-succinimidohexane, or 4-(O--CH.sub.2 CO--Gly--Gly--Cys.amide)acetophenone.

22. A reagent for preparing a thrombus imaging agent for imaging a thrombus within la mammalian body comprising a specific binding peptide having an amino acid sequence of 40 to 100 amino acids and a technetium-99m binding moiety covalently linked to the specific binding peptide, wherein the peptide is a ligand for a polymerization site of fibrin, having an amino acid sequence comprising multiple copies of the sequence (glycyl-prolyl-arginyl-prolyl).

23. A reagent for preparing a thrombus imaging agent for imaging a thrombus within a mammalian body comprising a specific binding peptide having an amino acid sequence of 4 to 100 amino acids and a technetium-99m binding moiety covalently linked to the specific binding peptide, wherein the reagent has the formula:

{(GPRP).sub.2 K}.sub.2 KC.sub.Acm GC.sub.Acm.amide,

(GPRVVERHQSA).sub.2 KC.sub.Acm GC.sub.Acm.amide,

(GPRPC.sub.Acm GC.sub.Acm C).sub.3 --TSEA,

{GPRPPPGGC.sub.Acm GC.sub.Acm GGC}.sub.3 --TSEA,

acetyl-CNP.Apc.GDC,

{BAT}.Hly.GDP.Hly.GDF.amide,

{BAT}G.Apc.GDV.Apc.GDFK.amide, ##STR19## acetyl-G.Apc.GDV.Apc.GDFKC.sub.Acm GC.sub.Acm.amide, G.Apc.GDV.Apc.GDFKC.sub.Acm GC.sub.Acm.amide, or

G.Apc.GDVKC.sub.Acm GC.sub.Acm.amide.

24. The reagent of claim 22, that is radiolabled with technetium-99m.

25. The reagent according to claim 22 wherein the specific-binding peptide and the technetium-99m binding moiety are covalently linked through from about to about 20 amino acids.

26. A complex formed by reacting the reagent according to claim 22 with technetium-99m in the presence of a reducing agent.

27. The complex of claim 26, wherein the reducing agent is selected from the group consisting of a dithionite ion, a stannous ion and a ferrous ion.

28. A complex formed by labeling the reagent according to claim 22 with technetium-99m by ligand exchange of a prereduced technetium-99m complex.

29. A composition of matter comprising the reagent according to claim 22 and a stannous ion.

30. A kit for preparing a radiopharmaceutical preparation, said kit comprising a sealed vial containing a predetermined quantity of a reagent according to claim 22 and a sufficient amount of reducing agent to label said reagent with technetium-99m.

31. A method for labeling a reagent according to claim 22 comprising reacting the reagent with technetium-99m in the presence of a reducing agent.

32. The method of claim 31, wherein the reducing agent is selected from the group consisting of a dithionite ion, a stannous ion and a ferrous ion.

33. A method for imaging a thrombus within a mammalian body comprising the steps of administering an effective diagnostic amount of the technetium-99m radiolabeled reagent of claim 26 to an animal and detecting the radiolabeled reagent localized at the site of a thrombus.

34. The reagent according to claim 22 wherein the specific-binding peptide is chemically synthesized in vitro.

35. The specific-binding peptide according to claim 34 wherein the peptide is synthesized by solid phase peptide synthesis.

36. The reagent according to claim 34 wherein the technetium-99m binding moiety is covalently linked to the peptide during in vitro chemical synthesis.

37. The reagent according to claim 36, wherein the technetium-99m binding moiety is covalently linked to the peptide during solid phase peptide synthesis.

38. The reagent of claim 22 wherein the reagent further comprises a polyvalent linking moiety covalently linked to a multiplicity of specific binding compounds and also covalently linked to a multiplicity of radiolabel-binding moieties to comprise a reagent for preparing a multimeric polyvalent scintigraphic imaging agent, wherein the molecular weight of the multimeric polyvalent scintigraphic imaging agent is less than about 20,000 daltons.

39. The reagent of claim 38 wherein the polyvalent linking moiety is bis-succinimidylmethylether, 4-(2,2-dimethylacetyl)benzoic acid, N-[2-(N',N'-bis(2-succinimidoethyl)aminoethyl)]--N.sup.6,N.sup.9 -bis(2-methyl-2-mercaptopropyl)-6,9-diazanonanamide, tris(succinimidylethyl)amine, bis-succinimidohexane, or 4-(O--CH.sub.2 CO--Gly--Gly--Cys.amide)acetophenone.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc